marketcaparena
Search

    BEAT

    HeartBeam, Inc.

    Company overview

    Market capitalization
    $21.02M
    Employees
    16
    Latest publication
    2026-09-29
    About HeartBeam, Inc.

    HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD0USD0USD
    Cost Of Revenue24,000USD-8,000USD8,000USD8,000USD7,000USD7,000USD——
    Gross Profit-24,000USD8,000USD-8,000USD-8,000USD-7,000USD-7,000USD——
    Research Development2,370,000USD3,354,000USD3,278,000USD3,326,000USD3,492,000USD2,886,000USD2,893,000USD2,844,000USD
    Selling General Administrative2,346,000USD1,956,000USD2,012,000USD1,711,000USD2,012,000USD2,058,000USD2,176,000USD2,246,000USD
    Total Operating Expenses4,692,000USD5,310,000USD5,290,000USD5,037,000USD5,504,000USD4,944,000USD5,069,000USD5,090,000USD
    Operating Income-4,716,000USD-5,310,000USD-5,290,000USD-5,037,000USD-5,504,000USD-4,944,000USD-5,069,000USD-5,090,000USD
    Interest Income16,000USD5,000USD36,000USD63,000USD20,000USD38,000USD96,000USD134,000USD
    Net Interest Income16,000USD5,000USD36,000USD63,000USD20,000USD38,000USD96,000USD134,000USD
    Income Before Tax-4,700,000USD-5,302,000USD-5,255,000USD-4,974,000USD-5,484,000USD-4,907,000USD-4,979,000USD-4,956,000USD
    Tax Provision0USD0USD0USD0USD0USD0USD0USD0USD
    Net Income-4,700,000USD-5,302,000USD-5,255,000USD-4,974,000USD-5,484,000USD-4,907,000USD-4,979,000USD-4,956,000USD
    Net Income From Continuing Ops-4,700,000USD-5,302,000USD-5,255,000USD-4,974,000USD-5,484,000USD-4,907,000USD-4,979,000USD-4,956,000USD
    Ebit-4,716,000USD-5,310,000USD-5,290,000USD-5,037,000USD-5,504,000USD-4,944,000USD4,805,000USD-9,734,000USD
    Ebitda-4,692,000USD-5,293,000USD-5,282,000USD-5,029,000USD-5,497,000USD-4,942,250USD-5,069,000USD-5,090,000USD
    Depreciation And Amortization24,000USD17,000USD8,000USD8,000USD7,000USD1,750USD-9,874,000USD5,090,000USD
    Reconciled Depreciation24,000USD17,000USD8,000USD8,000USD7,000USD—0USD0USD
    Total Other Income Expense Net16,000USD8,000USD35,000USD63,000USD20,000USD37,000USD90,000USD134,000USD
    Income Tax Expense—————9,874,000USD—-5,090,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD439,107,000USD399,472,000USD
    Cost Of Revenue40,000USD7,000USD————164,833,000USD148,986,000USD
    Gross Profit-40,000USD-7,000USD————274,274,000USD250,486,000USD
    Research Development13,450,000USD11,051,000USD6,798,000USD5,677,000USD255,000USD133,000USD41,000USD11,206,000USD
    Selling General Administrative7,689,000USD8,836,000USD8,516,000USD7,354,000USD2,030,000USD655,000USD120,093,000USD112,427,000USD
    Total Operating Expenses21,139,000USD19,887,000USD15,314,000USD13,031,000USD2,285,000USD788,000USD294,000USD166,482,000USD
    Operating Income-21,139,000USD-19,887,000USD-15,314,000USD-13,031,000USD-2,285,000USD-788,000USD-294,000USD84,004,000USD
    Interest Income122,000USD446,000USD675,000USD66,000USD————
    Net Interest Income122,000USD446,000USD472,000USD66,000USD-2,165,000USD-280,000USD-242,000USD—
    Income Before Tax-21,015,000USD-19,448,000USD-14,639,000USD-12,962,000USD-4,428,000USD-1,068,000USD-536,000USD41,504,000USD
    Tax Provision0USD0USD0USD0USD0USD0USD0USD—
    Net Income-21,015,000USD-19,448,000USD-14,639,000USD-12,827,000USD-4,428,000USD-1,348,000USD-778,000USD42,820,000USD
    Net Income From Continuing Ops-21,015,000USD-19,448,000USD-14,472,000USD-12,962,000USD-4,428,000USD-1,068,000USD-536,000USD—
    Ebit-21,139,000USD-19,887,000USD-14,639,000USD-13,031,000USD-2,263,000USD-788,000USD-294,000USD51,879,000USD
    Ebitda-21,099,000USD-19,880,000USD675,000USD-12,896,000USD-2,285,000USD-788,000USD42,682,000USD92,047,000USD
    Depreciation And Amortization40,000USD7,000USD15,314,000USD135,000USD2,285,000USD788USD42,976,000USD40,168,000USD
    Reconciled Depreciation40,000USD7,000USD0USD—————
    Total Other Income Expense Net124,000USD439,000USD675,000USD69,000USD-2,143,000USD-280,000USD-242,000USD-42,500,000USD
    Income Tax Expense——-15,314USD-135,000USD2,165,000USD280,000USD242,000USD-370,000USD
    Interest Expense———66,000USD2,165,000USD280,000USD242,000USD9,429,000USD
    Net Income Applicable To Common Shares———-12,962,000USD-4,428,000USD-1,068,000USD-536,000USD—
    Unclassified Operating Expenses——————-119,840,000USD—
    Selling And Marketing Expenses———————42,849,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets10,637,000USD3,929,000USD5,843,000USD2,876,000USD5,981,000USD9,107,000USD3,276,000USD6,657,000USD
    Cash And Equivalents8,722,000USD———————
    Total Current Assets8,996,000USD2,435,000USD4,685,000USD2,126,000USD5,361,000USD8,608,000USD2,770,000USD6,144,000USD
    Other Current Assets164,000USD263,000USD202,000USD270,000USD308,000USD458,000USD393,000USD376,000USD
    Other Non Current Assets57,000USD———————
    Total Liabilities2,460,000USD———————
    Total Current Liabilities2,460,000USD3,294,000USD3,240,000USD2,470,000USD1,799,000USD1,578,000USD1,622,000USD1,856,000USD
    Other Current Liabilities1,852,000USD———————
    Total Stockholder Equity8,177,000USD635,000USD2,603,000USD406,000USD4,182,000USD7,529,000USD1,654,000USD4,801,000USD
    Total Equity Including Noncontrolling Interest8,177,000USD———————
    Inventory110,000USD133,000USD103,000USD———0USD—
    Property Plant Equipment Net1,584,000USD1,438,000USD1,102,000USD694,000USD564,000USD443,000USD450,000USD457,000USD
    Accounts Payable608,000USD747,000USD1,053,000USD1,021,000USD814,000USD523,000USD531,000USD1,851,000USD
    Common Stock6,000USD4,000USD4,000USD4,000USD4,000USD3,000USD3,000USD3,000USD
    Retained Earnings-87,027,000USD-81,988,000USD-77,288,000USD-71,986,000USD-66,731,000USD-61,757,000USD-56,273,000USD-51,366,000USD
    Total Liab—3,294,000USD3,240,000USD2,470,000USD1,799,000USD1,578,000USD1,622,000USD1,856,000USD
    Other Current Liab—3,294,000USD3,240,000USD1,449,000USD985,000USD1,055,000USD1,091,000USD5,000USD
    Capital Stock—4,000USD4,000USD4,000USD4,000USD3,000USD3,000USD3,000USD
    Cash—2,039,000USD4,380,000USD1,856,000USD3,256,000USD4,390,000USD2,377,000USD5,768,000USD
    Cash And Short Term Investments—2,039,000USD4,380,000USD1,856,000USD5,053,000USD8,150,000USD2,377,000USD5,768,000USD
    Net Debt—-2,039,000USD-4,380,000USD-1,856,000USD-3,256,000USD-4,390,000USD-2,377,000USD-5,768,000USD
    Property Plant Equipment Gross—1,509,000USD—694,000USD564,000USD443,000USD—457,000USD
    Common Stock Shares Outstanding—40,588,385shares33,710,095shares34,396,431shares33,834,950shares30,378,751shares26,747,893shares26,752,297shares
    Non Current Assets Total—1,494,000USD1,158,000USD750,000USD620,000USD499,000USD506,000USD513,000USD
    Non Current Liabilities Total—0USD0USD0USD0USD0USD0USD0USD
    Non Currrent Assets Other—56,000USD56,000USD56,000USD56,000USD56,000USD56,000USD56,000USD
    Net Working Capital—-859,000USD1,445,000USD-344,000USD3,562,000USD7,030,000USD1,148,000USD4,288,000USD
    Unclassified Equity—82,615,000USD79,883,000USD72,384,000USD70,905,000USD69,280,000USD57,921,000USD56,161,000USD
    Unclassified Current Liabilities——-1,053,000USD—————
    Short Term Investments————1,797,000USD3,760,000USD——
    Accumulated Other Comprehensive Income————0USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets5,843,000USD3,276,000USD17,131,000USD4,039,000USD13,998,000USD51,000USD7,000USD586,801,000USD
    Other Current Assets202,000USD393,000USD636,000USD445,000USD806,000USD27,000USD2,000USD5,820,000USD
    Total Liab3,240,000USD1,622,000USD1,194,000USD1,665,000USD588,000USD4,836,000USD3,734,000USD276,316,000USD
    Total Stockholder Equity2,603,000USD1,654,000USD15,937,000USD2,374,000USD13,410,000USD-4,785,000USD-3,727,000USD310,485,000USD
    Other Current Liab3,240,000USD1,091,000USD638,000USD2,000USD1,000USD67,000USD-23,885,690USD23,261,000USD
    Common Stock4,000USD3,000USD3,000USD1,000USD1,000USD1,000USD1,000USD33,000USD
    Capital Stock4,000USD3,000USD3,000USD1,000USD1,000USD0USD0USD—
    Retained Earnings-77,288,000USD-56,273,000USD-36,825,000USD-22,186,000USD-9,224,000USD-4,796,000USD-3,728,000USD-115,858,000USD
    Cash4,380,000USD2,377,000USD16,189,000USD3,594,000USD13,192,000USD24,000USD5,000USD80,889,000USD
    Cash And Short Term Investments4,380,000USD2,377,000USD16,189,000USD3,594,000USD13,192,000USD24,000USD5,000USD80,889,000USD
    Total Current Assets4,685,000USD2,770,000USD16,825,000USD4,039,000USD13,998,000USD51,000USD7,000USD146,660,000USD
    Total Current Liabilities3,240,000USD1,622,000USD1,194,000USD1,665,000USD588,000USD4,836,000USD354,000USD49,623,000USD
    Net Debt-4,380,000USD-2,377,000USD-16,189,000USD-3,594,000USD-13,192,000USD4,271,000USD3,417,000USD117,660,000USD
    Inventory103,000USD0USD————5,738,000USD7,323,000USD
    Accounts Payable1,053,000USD531,000USD556,000USD1,663,000USD587,000USD474,000USD24,198,000USD18,157,000USD
    Property Plant Equipment Net1,102,000USD450,000USD256,000USD0USD——56,380,000USD48,377,000USD
    Common Stock Shares Outstanding33,710,095shares26,645,228shares20,333,280shares8,168,516shares7,809,912shares8,167,400shares8,167,400shares35,783,000shares
    Non Current Assets Total1,158,000USD506,000USD306,000USD0USD806,000USD0USD517,387,000USD440,141,000USD
    Non Current Liabilities Total0USD0USD0USD0USD0USD4,295,000USD3,380,000USD226,693,000USD
    Non Currrent Assets Other56,000USD56,000USD50,000USD—806,000USD—-499,923,000USD3,322,000USD
    Net Working Capital1,445,000USD1,148,000USD15,631,000USD2,374,000USD13,410,000USD-4,785,000USD-347,000USD—
    Unclassified Current Liabilities-1,053,000USD————-4,295,000USD-23,928,000USD—
    Unclassified Equity79,883,000USD57,921,000USD52,756,000USD24,558,000USD22,632,000USD——493,512,000USD
    Other Assets———445,000USD-806,000USD———
    Net Tangible Assets———2,374,000USD13,410,000USD-4,785,000USD-3,727,000USD—
    Accumulated Other Comprehensive Income————0USD—0USD-67,202,000USD
    Current Deferred Revenue—————-474USD-310USD3,080,000USD
    Short Term Debt—————4,295,000USD42,000USD5,125,000USD
    Short Long Term Debt—————4,295,000USD42,000USD—
    Short Long Term Debt Total—————4,295,000USD3,422,000USD198,549,000USD
    Unclassified Non Current Liabilities—————4,295,000USD—226,693,000USD
    Intangible Assets——————129,596,000USD129,653,000USD
    Good Will——————301,321,000USD238,814,000USD
    Long Term Debt——————3,380,000USD—
    Net Receivables——————87,476,000USD52,628,000USD
    Unclassified Current Assets——————-93,214,000USD—
    Unclassified Non Current Assets——————30,090,000USD19,975,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation81,000USD
    Stock Based Compensation2,918,000USD
    Change To Inventory-7,000USD
    Change To Liabilities-848,000USD
    Change In Working Capital-817,000USD
    Operating Cash Flow-6,952,000USD
    Capital Expenditures-495,000USD
    Investing Cash Flow-495,000USD
    Financing Cash Flow11,790,000USD
    Change In Cash4,343,000USD
    End Cash Flow8,779,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-4,700,000USD-5,302,000USD-5,255,000USD-4,974,000USD-5,484,000USD-4,907,000USD-4,979,000USD-4,956,000USD
    Depreciation24,000USD17,000USD8,000USD8,000USD7,000USD7,000USD0USD0USD
    Stock Based Compensation1,217,000USD1,427,000USD1,434,000USD1,177,000USD1,109,000USD999,000USD1,053,000USD1,040,000USD
    Other Non Cash Items1,217,000USD226,000USD888,000USD344,000USD—7,000USD922,000USD1,040,000USD
    Change To Inventory-30,000USD-103,000USD——0USD———
    Change In Working Capital-151,000USD726,000USD653,000USD344,000USD-109,000USD-251,000USD-302,000USD366,000USD
    Total Cash From Operating Activities-3,610,000USD-2,906,000USD-3,160,000USD-3,445,000USD-4,477,000USD-4,152,000USD-3,306,000USD-3,550,000USD
    Capital Expenditures-246,000USD-416,000USD-82,000USD-102,000USD0USD0USD-103,000USD-10,000USD
    Free Cash Flow-3,856,000USD-3,322,000USD-3,242,000USD-3,547,000USD-4,477,000USD-4,152,000USD-3,409,000USD-3,560,000USD
    Investments0USD0USD1,715,000USD1,861,000USD-3,760,000USD0USD-103,000USD-10,000USD
    Total Cashflows From Investing Activities-246,000USD-416,000USD1,715,000USD1,861,000USD-3,760,000USD—-103,000USD-10,000USD
    Total Cash From Financing Activities1,515,000USD5,846,000USD45,000USD450,000USD10,250,000USD761,000USD21,000USD84,000USD
    Issuance Of Capital Stock1,515,000USD5,834,000USD44,000USD450,000USD10,250,000USD654,000USD0USD76,000USD
    Change In Cash-2,341,000USD2,524,000USD-1,400,000USD-1,134,000USD2,013,000USD-3,391,000USD-3,388,000USD-3,481,000USD
    Begin Period Cash Flow4,380,000USD1,912,000USD3,312,000USD4,446,000USD2,433,000USD5,824,000USD9,212,000USD12,638,000USD
    End Period Cash Flow2,039,000USD4,436,000USD1,912,000USD3,312,000USD4,446,000USD2,433,000USD5,824,000USD9,157,000USD
    Other Cashflows From Financing Activities1,515,000USD16,590,000USD1,000USD450,000USD10,250,000USD107,000USD21,000USD8,000USD
    Unclassified Operating Cash Flow-1,217,000USD——————-1,040,000USD
    Unclassified Financing Cash Flow-1,515,000USD-16,578,000USD——-10,250,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-21,015,000USD-19,448,000USD-14,639,000USD-12,962,000USD-4,428,000USD-1,068,000USD-536,000USD42,820,000USD
    Depreciation40,000USD7,000USD0USD———42,976,000USD40,168,000USD
    Stock Based Compensation5,147,000USD4,299,000USD3,208,000USD1,120,000USD192,000USD10,000USD0USD9,261,000USD
    Other Non Cash Items226,000USD671,000USD3,208,000USD1,120,000USD2,142,000USD276,000USD242,000USD-75,093,000USD
    Change To Inventory-103,000USD0USD————1,585,000USD-1,991,000USD
    Change In Working Capital1,614,000USD671,000USD-662,000USD1,894,000USD-1,136,000USD182,000USD76,000USD57,884,000USD
    Total Cash From Operating Activities-13,988,000USD-14,471,000USD-12,093,000USD-9,948,000USD-3,230,000USD-600,000USD-218,000USD72,746,000USD
    Capital Expenditures-600,000USD-201,000USD-256,000USD0USD0USD0USD-30,707,000USD-24,637,000USD
    Free Cash Flow-14,588,000USD-14,672,000USD-12,349,000USD-9,948,000USD-3,230,000USD-600,000USD-218,000USD48,109,000USD
    Investments0USD-201,000USD-256,000USD0USD————
    Total Cashflows From Investing Activities-600,000USD-201,000USD-256,000USD————-28,851,000USD
    Total Cash From Financing Activities16,591,000USD866,000USD24,994,000USD350,000USD16,398,000USD619,000USD206,000USD601,000USD
    Issuance Of Capital Stock16,578,000USD730,000USD24,764,000USD348,000USD14,713,000USD0USD——
    Change In Cash2,003,000USD-13,806,000USD12,645,000USD-9,598,000USD13,168,000USD19,000USD-12,000USD44,867,000USD
    Begin Period Cash Flow2,433,000USD16,239,000USD3,594,000USD13,192,000USD24,000USD5,000USD17,000USD36,022,000USD
    End Period Cash Flow4,436,000USD2,433,000USD16,239,000USD3,594,000USD13,192,000USD24,000USD5,000USD80,889,000USD
    Other Cashflows From Financing Activities16,591,000USD136,000USD460,000USD2,000USD1,715,000USD619,000USD140,000USD601,000USD
    Unclassified Financing Cash Flow-16,578,000USD———-1,715,000USD———
    Unclassified Operating Cash Flow——-3,208,000USD-1,120,000USD——-42,976,000USD-2,294,000USD
    Change To Liabilities———1,533,000USD-357,000USD207,000USD78,000USD—
    Net Borrowings———0USD1,685,000USD619,000USD206,000USD—
    Change To Account Receivables———————-40,922,000USD
    Other Cashflows From Investing Activities———————-4,214,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2020Quarterly · 2020-09-30ProductClinical Trial Supportand Related Services12,117,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30ProductMonitoring Commercial57,051,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30ProductMonitoring Medicare41,417,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30ProductTechnology Devices Consumablesand Related Services4,070,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30SegmentOther4,070,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30SegmentPatient Service98,468,000USD0001574774-20-000106
    Q3 2020Quarterly · 2020-09-30SegmentResearch Services12,117,000USD0001574774-20-000106
    Q2 2020Quarterly · 2020-06-30ProductClinical Trial Supportand Related Services11,459,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30ProductMonitoring Commercial41,399,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30ProductMonitoring Medicare33,281,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30ProductTechnology Devices Consumablesand Related Services3,268,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30SegmentOther3,268,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30SegmentPatient Service74,680,000USD0001574774-20-000095
    Q2 2020Quarterly · 2020-06-30SegmentResearch Services11,459,000USD0001574774-20-000095
    Q1 2020Quarterly · 2020-03-31ProductClinical Trial Supportand Related Services13,820,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31ProductMonitoring Commercial55,579,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31ProductMonitoring Medicare40,128,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31ProductTechnology Devices Consumablesand Related Services3,504,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31SegmentOther3,504,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31SegmentPatient Service95,707,000USD0001574774-20-000047
    Q1 2020Quarterly · 2020-03-31SegmentResearch Services13,820,000USD0001574774-20-000047
    Q4 2019Quarterly · 2019-12-31ProductClinical Trial Supportand Related Services13,371,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductMonitoring Commercial50,953,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductMonitoring Medicare44,175,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductTechnology Devices Consumablesand Related Services3,535,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31SegmentCorporate And Other3,535,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31SegmentPatient Service95,128,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31SegmentResearch Services13,371,000USDLegacy provider
    FY 2019Yearly · 2019-12-31ProductClinical Trial Supportand Related Services54,450,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31ProductMonitoring Commercial218,271,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31ProductMonitoring Medicare153,743,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31ProductTechnology Devices Consumablesand Related Services12,643,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31SegmentCorporate And Other12,643,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31SegmentPatient Service372,014,000USD0001574774-20-000032
    FY 2019Yearly · 2019-12-31SegmentResearch Services54,450,000USD0001574774-20-000032
    Q3 2019Quarterly · 2019-09-30ProductClinical Trial Supportand Related Services14,236,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30ProductMonitoring Commercial54,336,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30ProductMonitoring Medicare39,537,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30ProductTechnology Devices Consumablesand Related Services3,182,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30SegmentOther3,182,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30SegmentPatient Service93,873,000USD0001574774-20-000106
    Q3 2019Quarterly · 2019-09-30SegmentResearch Services14,236,000USD0001574774-20-000106
    Q2 2019Quarterly · 2019-06-30ProductClinical Trial Supportand Related Services13,879,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30ProductMonitoring Commercial58,908,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30ProductMonitoring Medicare36,096,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30ProductTechnology Devices Consumablesand Related Services2,920,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30SegmentOther2,920,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30SegmentPatient Service95,004,000USD0001574774-20-000095
    Q2 2019Quarterly · 2019-06-30SegmentResearch Services13,879,000USD0001574774-20-000095
    Q1 2019Quarterly · 2019-03-31ProductClinical Trial Supportand Related Services12,964,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31ProductMonitoring Commercial54,074,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31ProductMonitoring Medicare33,935,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31ProductTechnology Devices Consumablesand Related Services3,006,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31SegmentOther3,006,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31SegmentPatient Service88,009,000USD0001574774-20-000047
    Q1 2019Quarterly · 2019-03-31SegmentResearch Services12,964,000USD0001574774-20-000047
    Q4 2018Quarterly · 2018-12-31ProductClinical Trial Supportand Related Services13,307,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31ProductMonitoring Commercial51,194,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31ProductMonitoring Medicare36,148,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31ProductTechnology Devices Consumablesand Related Services2,954,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31SegmentCorporate And Other2,954,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31SegmentPatient Service87,342,000USDLegacy provider
    Q4 2018Quarterly · 2018-12-31SegmentResearch Services13,307,000USDLegacy provider
    FY 2018Yearly · 2018-12-31ProductClinical Trial Supportand Related Services50,561,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31ProductMonitoring Commercial201,212,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31ProductMonitoring Medicare137,600,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31ProductTechnology Devices Consumablesand Related Services10,099,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31SegmentCorporate And Other10,099,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31SegmentPatient Service338,812,000USD0001574774-20-000032
    FY 2018Yearly · 2018-12-31SegmentResearch Services50,561,000USD0001574774-20-000032
    FY 2017Yearly · 2017-12-31SegmentOther13,601,000USD0001574774-20-000032
    FY 2017Yearly · 2017-12-31SegmentPatient Service234,385,000USD0001574774-20-000032
    FY 2017Yearly · 2017-12-31SegmentResearch Services38,790,000USD0001574774-20-000032
    FY 2016Yearly · 2016-12-31SegmentOther10,103,000USD0001574774-19-000018
    FY 2016Yearly · 2016-12-31SegmentPatient Service165,664,000USD0001574774-19-000018
    FY 2016Yearly · 2016-12-31SegmentResearch Services32,565,000USD0001574774-19-000018
    FY 2015Yearly · 2015-12-31SegmentPatient Service145,963,000USD0001047469-17-000837
    FY 2015Yearly · 2015-12-31SegmentProduct10,697,000USD0001047469-17-000837
    FY 2015Yearly · 2015-12-31SegmentResearch Services21,853,000USD0001047469-17-000837
    FY 2014Yearly · 2014-12-31SegmentPatient Service133,178,000USD0001047469-17-000837
    FY 2014Yearly · 2014-12-31SegmentProduct13,656,000USD0001047469-17-000837
    FY 2014Yearly · 2014-12-31SegmentResearch Services19,744,000USD0001047469-17-000837
    FY 2013Yearly · 2013-12-31SegmentPatient Service100,386,000USD0001047469-16-010284
    FY 2013Yearly · 2013-12-31SegmentProduct8,786,000USD0001047469-16-010284
    FY 2013Yearly · 2013-12-31SegmentResearch Services20,329,000USD0001047469-16-010284
    FY 2012Yearly · 2012-12-31SegmentPatient Service93,640,000USD0001047469-14-001401
    FY 2012Yearly · 2012-12-31SegmentProduct9,521,000USD0001047469-14-001401
    FY 2012Yearly · 2012-12-31SegmentResearch Services8,333,000USD0001047469-14-001401

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.